Business Context and Reporting Period
Company: Anika Therapeutics, Inc. (NASDAQ: ANIK)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Anika is a global joint preservation company focusing on Osteoarthritis (OA) Pain Management and Regenerative Solutions using proprietary hyaluronic acid (HA) technology. In 2024 and 2025, the company executed a strategic shift to concentrate on these core portfolios, divesting Arthrosurface Incorporated (October 2024) and Parcus Medical, LLC (March 2025).
Key Products: Monovisc, Orthovisc, and Cingal (OA Pain Management); Integrity, Hyalofast, and Tactoset (Regenerative Solutions).
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $112.8 million | $119.9 million | (6%) |
| Gross Profit | $63.8 million | $76.0 million | (16%) |
| Gross Margin | 57% | 63% | -600 bps |
| Operating Loss | $(11.1) million | $(5.1) million | Worsened |
| Net Loss (Continuing Ops) | $(10.0) million | $(8.8) million | Worsened |
| Net Loss (Total) | $(10.9) million | $(56.4) million | Improved (81%) |
| Operating Cash Flow | $11.2 million | $5.4 million | Positive |
| Cash & Equivalents | $57.5 million | $55.6 million | Stable |
| Debt | $0 (No borrowings) | $0 | N/A |
Note: The significant improvement in Total Net Loss compared to 2024 is primarily due to the reclassification of Arthrosurface and Parcus Medical results as "Discontinued Operations," which generated a $47.6 million loss in 2024 but only a $0.9 million loss in 2025.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 6% to $112.8 million. The OEM Channel (primarily J&J MedTech) declined 17% due to lower pricing ($10.0M impact) and lower volumes ($2.6M impact). Conversely, the Commercial Channel grew 15% driven by international sales of Cingal and Orthovisc, and the U.S. launch of the Integrity Implant System.
- Margin Compression: Gross margin contracted from 63% to 57%. This was driven by lower revenue, a shift in product mix toward international sales (which have lower selling prices), increased manufacturing costs, and higher inventory reserves.
- Divestitures Completed: The company completed the sale of Arthrosurface (Oct 2024) and Parcus Medical (Mar 2025). Proceeds included a $7.0M note receivable from Arthrosurface and $4.5M cash from Parcus. These assets are now reported as discontinued operations.
- Executive Transition: Effective February 1, 2026, Stephen Griffin replaced Cheryl Blanchard as President and CEO. Blanchard became Executive Chair.
Guidance, Outlook, and Risks
Outlook and Pipeline
- Cingal (U.S. Approval): The company is actively engaging with the FDA for U.S. approval of Cingal, a next-generation OA pain product. A bioequivalence study was initiated in 2025. The company targets a U.S. launch upon approval, addressing a ~$1 billion market.
- Hyalofast (PMA Deficiency): A Premarket Approval (PMA) application for Hyalofast (cartilage repair) was submitted in October 2025. In January 2026, the FDA issued a deficiency letter citing issues with Chemistry, Manufacturing, and Controls (CMC) and statistical analysis plans. The company is preparing a response but faces uncertainty regarding approval timelines.
- Integrity: The Integrity Implant System continues to show strong growth in surgeries and adoption in the U.S. rotator cuff repair market.
Key Risks and Contingencies
- Customer Concentration: J&J MedTech accounted for 50% of total revenue in 2025. J&J MedTech announced plans to divest its orthopedics implants business, which includes Monovisc and Orthovisc, creating uncertainty for future revenue streams.
- Regulatory Uncertainty: Delays or failures in obtaining FDA approval for Cingal and Hyalofast could materially impact future growth. The Hyalofast PMA deficiency letter represents a significant near-term hurdle.
- Manufacturing & Supply Chain: The company relies on a single manufacturing site in Bedford, Massachusetts, and a small number of suppliers for key raw materials.
- Activist Stockholders: The company has engaged in cooperation agreements with Caligan Partners LP, which has influenced board composition and strategic decisions, including the share repurchase program.
Investor Verification Checklist
- J&J MedTech Divestiture Impact: Verify the status of J&J MedTech's planned divestiture of the orthopedics business and how Anika plans to mitigate the risk of losing its largest customer (50% of revenue).
- Hyalofast FDA Response: Monitor the company's response to the January 2026 FDA deficiency letter regarding the Hyalofast PMA and the likelihood of approval without further clinical trials.
- Cingal U.S. Timeline: Track progress on the bioequivalence study and FDA meetings to estimate the probability and timing of U.S. commercialization.
- Inventory Reserves: Review the $4.8 million inventory reserve balance and assess if further write-downs are necessary given the shift in product mix and demand.
- CEO Transition: Evaluate the strategic direction under the new CEO, Stephen Griffin, particularly regarding the balance between R&D investment and cost management.